Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.53 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225122 | 1.00 | TSHR (0.53) | TSHRTP53EGLN1EGLN3LDHA | |
| SCHEMBL2780998 | 1.00 | TSHR (0.53) | TSHRTP53EGLN1EGLN3LDHA | |
| SCHEMBL12568561 | 0.91 | TSHR (0.64) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleylacetoacetate SCHEMBL380205 | 0.87 | TSHR (0.45) | TSHRTP53EGLN1EGLN3LDHA | |
| Maleylacetoacetate SCHEMBL187565 | 0.87 | TSHR (0.45) | TSHRTP53EGLN1EGLN3LDHA | |
| Maleylacetoacetate SCHEMBL187863 | 0.87 | TSHR (0.45) | TSHRTP53EGLN1EGLN3LDHA | |
| Fumaric Acid SCHEMBL28422912 | 0.84 | TSHR (0.64) | TSHRTP53EGLN1EGLN3LDHA | |
| Maleic Acid SCHEMBL1038087 | 0.84 | TSHR (0.64) | TSHRTP53EGLN1EGLN3LDHA | |
| Fumaric Acid SCHEMBL1038089 | 0.84 | TSHR (0.64) | TSHRTP53EGLN1EGLN3LDHA | |
| SCHEMBL23361428 | 0.80 | TSHR (0.50) | TSHRTP53EGLN1EGLN3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130990-A1 | METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV | ULTRAGENYX PHARMACEUTICAL INC (US) | 2026-05-14 | — | — | US | claimed |
| US-12544437-B2 | Methods for improved therapeutic use of recombinant AAV | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2026-02-10 | — | — | US | claimed |
| US-20230235353-A1 | COMPOSITIONS AND METHODS FOR REDUCING REVERSE PACKAGING OF CAP AND REP SEQUENCES IN RECOMBINANT AAV | ULTRAGENYX PHARMACEUTICAL INC (US) | 2023-07-27 | — | — | US | claimed |
| EP-4121544-A1 | COMPOSITIONS AND METHODS FOR REDUCING REVERSE PACKAGING OF CAP AND REP SEQUENCES IN RECOMBINANT AAV | Ultragenyx Pharmaceutical Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| US-20220347298-A1 | METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV | ULTRAGENYX PHARMACEUTICAL INC. | 2022-11-03 | — | — | US | claimed |
| EP-4038194-A1 | METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV | Ultragenyx Pharmaceutical Inc. (US) | 2022-08-10 | — | — | EP | claimed |
| US-20260130990-A1 | METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV | ULTRAGENYX PHARMACEUTICAL INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12600989-B2 | Adeno-associated virus (AAV) vector and uses therefor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260070935-A1 | BISPHOSPHONATE LIPIDS, LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME, MINERAL TISSUE-ADSORBED COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF | UNIV PENNSYLVANIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260063601-A1 | PLASMA METABOLOME AS A PREDICTOR OF BIOLOGICAL AGING | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260049334-A1 | NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS HAVING REDUCED CAPSID DEAMIDATION AND USES THEREFOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-02-19 | — | — | US | disclosed |
| US-12544437-B2 | Methods for improved therapeutic use of recombinant AAV | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260028651-A1 | METHOD OF PRODUCING & PROCESSING DIAMINES | AGAIN BIO APS (DK) | 2026-01-29 | — | — | US | disclosed |
| US-8377680-B2 | Microorganisms and methods for the biosynthesis of adipate, hexamethylenediamine and 6-aminocaproic acid | GENOMATICA, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| WO-2012177721-A1 | MICROORGANISMS FOR PRODUCING 6-AMINOCAPROIC ACID | GENOMATICA, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120282661-A1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID | GENOMATICA, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| WO-2012018624-A2 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF AROMATICS, 2,4-PENTADIENOATE AND 1,3-BUTADIENE | GENOMATICA, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2010144746-A2 | MICROORGANISMS AND METHODS FOR CARBON-EFFICIENT BIOSYNTHESIS OF MEK AND 2-BUTANOL | GENOMATICA, INC. (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317069-A1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID | AGAIN BIO APS (DK) | 2010-12-16 | — | — | US | disclosed |
| WO-2010129936-A1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID | GENOMATICA, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600989-B2 | Adeno-associated virus (AAV) vector and uses therefor | IGF2BP1, HAVCR2, CPSF6 | TSHR 1734/4885TP53 658/4885EGLN1 2719/4885 |
| US-20260063601-A1 | PLASMA METABOLOME AS A PREDICTOR OF BIOLOGICAL AGING | PLPBP, PLCG1, PLA2G1B | TSHR 2218/4885TP53 2672/4885EGLN1 758/4885 |
| US-20260028651-A1 | METHOD OF PRODUCING & PROCESSING DIAMINES | DDC, DAO, ODC1 | TSHR 3382/4885TP53 1346/4885EGLN1 479/4885 |
| US-20260070935-A1 | BISPHOSPHONATE LIPIDS, LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME, MINERAL TISSUE-ADSORBED COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF | BCR, PHOSPHO1, BST2 | TSHR 3021/4885TP53 1432/4885EGLN1 675/4885 |
| US-20260130990-A1 | METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAV | ICOS, ICOSLG, LY6K | TSHR 786/4885TP53 4432/4885EGLN1 4427/4885 |
| US-20260049334-A1 | NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS HAVING REDUCED CAPSID DEAMIDATION AND USES THEREFOR | ASNS, VSIG8, GOT1 | TSHR 3495/4885TP53 878/4885EGLN1 858/4885 |
| US-12544437-B2 | Methods for improved therapeutic use of recombinant AAV | ICOS, CD22, HAVCR2 | TSHR 1014/4885TP53 2847/4885EGLN1 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.